{"id":"NCT01059344","sponsor":"Tillotts Pharma AG","briefTitle":"Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis","officialTitle":"A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2011-07","completion":"2011-08","firstPosted":"2010-01-29","resultsPosted":"2017-04-24","lastUpdate":"2017-08-02"},"enrollment":281,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Mesalamin","otherNames":["Asacol"]}],"arms":[{"label":"Mesalamin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to placebo in subjects with active ulcerative colitis (UC).","primaryOutcome":{"measure":"To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC).","timeFrame":"6 weeks","effectByArm":[{"arm":"Mesalamin","deltaMin":42,"sd":null},{"arm":"Placebo","deltaMin":29,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.069"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["Belarus","India","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["23528626"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":140},"commonTop":["Colitis ulcerosa","Anaemia","Monozytopenia"]}}